Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Profound Medical Corp. is a medical technology company focused on the development and commercialization of minimally invasive therapeutic systems that combine magnetic resonance imaging (MRI) with robotically driven focused ultrasound. The company operates within the medical devices and urologic oncology industries, with a primary focus on prostate disease treatment. Its core product is the TULSA-PRO® System, which is designed to provide incision-free, MRI-guided ultrasound ablation of prostate tissue.
The company’s primary revenue driver is the sale and utilization of the TULSA-PRO® System, along with recurring revenue from disposable components and service agreements. Profound Medical primarily serves hospitals, academic medical centers, and specialized urology clinics, targeting physicians treating prostate cancer and benign prostatic hyperplasia (BPH). Its strategic positioning is based on offering precise, image-guided therapy that aims to reduce side effects compared with surgery or radiation. Profound Medical was founded in 2008 and has evolved from a research-stage company into a commercial-stage organization following regulatory clearances in the United States and other international markets.
Business Operations
Profound Medical operates through a single primary business segment centered on the development, manufacturing, and commercialization of the TULSA-PRO® System. Revenue is generated through capital equipment sales, recurring disposable usage, and service and maintenance contracts. The system integrates real-time MRI thermometry, proprietary ultrasound applicators, and robotic controls to enable controlled thermal ablation of prostate tissue.
Operations are geographically diversified, with commercial activities in the United States, Europe, and select international markets. The company maintains direct sales operations in key markets and utilizes distributor partnerships in certain regions. Profound Medical controls its core intellectual property related to MRI-guided ultrasound technology and has established clinical and research collaborations with leading academic hospitals to support clinical adoption and evidence generation.
Strategic Position & Investments
Profound Medical’s strategic direction centers on expanding adoption of the TULSA-PRO® System as a standard-of-care option for prostate disease by increasing clinical evidence, physician training, and reimbursement coverage. Growth initiatives include expanding U.S. commercial penetration, broadening indications within prostate disease, and increasing utilization at existing customer sites.
The company has historically invested in clinical trials and post-market studies to support regulatory approvals and guideline inclusion. Profound Medical does not operate a diversified investment portfolio and has no material unrelated business acquisitions disclosed in public filings. Its strategic focus remains concentrated on advancing MRI-guided ultrasound as a differentiated therapeutic platform within urology, with emerging interest in broader applications of its technology, although data on expansion beyond prostate indications is limited in public disclosures.
Geographic Footprint
Profound Medical is headquartered in Mississauga, Ontario, Canada, and maintains significant operational and commercial presence in the United States, which represents its most important market. The company also has an established footprint in Europe, including regulatory approvals and clinical use in multiple countries, and maintains distributor-supported sales in other international regions.
Manufacturing, research and development, and corporate functions are primarily based in Canada, while commercial and clinical support teams are deployed across North America and Europe. The company’s international influence is primarily operational rather than investment-based, focused on expanding system placements and clinical adoption in developed healthcare markets.
Leadership & Governance
Profound Medical is led by an executive team with experience in medical devices, imaging technologies, and commercial-stage healthcare companies. The leadership emphasizes clinical evidence generation, disciplined commercialization, and long-term adoption of minimally invasive therapies supported by strong physician training and outcomes data.
Key executives include:
- Artemis D. Markowski – Chief Executive Officer
- Jason E. Hurst – Chief Financial Officer
- Aaron N. Pavone – Chief Commercial Officer
- Stephen A. May – Chief Operating Officer
- Patrick Cheung – Vice President, Research & Development
The company operates under a board-governed structure consistent with publicly traded medical technology firms and follows governance and disclosure practices outlined in its SEC filings, including its annual reports and management discussion documents.